HSPC Gene Therapy: Automated Clinical-Scale Manufacturing via CCR5

bioRxiv USA

Overview

Researchers have demonstrated a fully automated, high-throughput manufacturing platform for hematopoietic stem and progenitor cell (HSPC) gene therapy. The system produces gene-edited HSPCs with an anti-HIV antibody transgene at the CCR5 locus while maintaining purity, differentiation potential, and in vivo function. This automation addresses the cost and scalability limitations of manual workflows to broaden patient access.

In Depth

Key Findings

The study confirms that clinical-scale doses of gene-edited HSPCs (geHSPCs) can be produced using a fully automated, high-throughput manufacturing platform without compromising key product attributes. The process successfully integrated an anti-HIV antibody transgene at the CCR5 locus, achieving editing efficiencies comparable to small-scale processing. Furthermore, geHSPCs transplanted into mice demonstrated the ability to engraft and reconstitute multiple hematopoietic lineages, proving that repopulation capacity remains preserved after automated processing.

Technical Details

The automated platform executes an end-to-end workflow designed for clinical-scale production. The sequence of operations includes:

• Post-thaw HSPC inoculation
• Cas9 electroporation
• AAV6 transduction
• Harvesting of the final product

The resulting geHSPCs exhibited high purity and preserved differentiation potential, meeting the necessary release criteria for therapeutic use.

Background & Context

Gene therapies utilizing HSPCs offer curative potential for various hematologic diseases. However, the industry has relied heavily on manual manufacturing workflows, which are costly and difficult to scale. These inefficiencies create a bottleneck that limits patient access to these potentially curative treatments.

Significance & Outlook

By transitioning from manual to automated, high-throughput manufacturing, this approach provides a path toward more cost-effective and scalable production of HSPC gene therapies. The ability to maintain in vivo function and product quality at a clinical scale suggests that automated platforms can overcome current manufacturing barriers, potentially increasing the availability of these therapies for a larger patient population.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime